Abstract
..
Main
..
Feedback
Home
c19early.org COVID-19 treatment researchNiclosamideNiclosamide (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Niclosamide for COVID-19: real-time meta analysis of 6 studies

@CovidAnalysis, February 2025, Version 6V6
Post
Share
PDF
Studies
Feedback
https://c19early.org/ncmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cairns (DB RCT) 66% 0.34 [0.01-7.98] severe case 0/33 1/34 Improvement, RR [CI] Treatment Control Cairns (DB RCT) 18% 0.82 [0.58-1.17] recov. time 33 (n) 34 (n) Cairns (DB RCT) 24% 0.76 [0.41-1.39] viral+ 11/33 15/34 FINCOV Siripongbo.. (RCT) 0% 1.00 [0.07-15.3] progression 1/30 1/30 CT​1​ FINCOV Siripongbo.. (RCT) 67% 0.33 [0.01-7.87] progression 0/30 1/30 CT​1​ FINCOV Siripongbo.. (RCT) 39% 0.61 [0.28-1.29] symp. score 30 (n) 30 (n) CT​1​ FINCOV Siripongbo.. (RCT) 70% 0.30 [0.09-0.99] symp. score 30 (n) 30 (n) CT​1​ FINCOV Siripongbo.. (RCT) 14% 0.86 [0.61-1.20] symp. score 30 (n) 30 (n) CT​1​ FINCOV Siripongbo.. (RCT) 67% 0.33 [0.03-4.37] symp. score 30 (n) 30 (n) CT​1​ FINCOV Siripongbo.. (RCT) 50% 0.50 [0.13-1.95] symp. score 30 (n) 30 (n) CT​1​ FINCOV Siripongbo.. (RCT) 6% 0.94 [0.65-1.35] viral+ 30 (n) 30 (n) CT​1​ Abdulamir (RCT) 0% 1.00 [0.21-4.80] death 3/75 3/75 Abdulamir (RCT) 39% 0.61 [0.43-0.87] no recov. 75 (n) 75 (n) RESERVOIR First Wa.. (DB RCT) 23% 0.77 [0.33-1.82] viral+ 8/60 10/58 RESERVOIR First Wa.. (DB RCT) 33% 0.67 [0.31-1.44] viral+ 9/60 13/58 RESERVOIR First Wa.. (DB RCT) 42% 0.58 [0.28-1.22] viral+ 9/60 15/58 RESERVOIR First Wa.. (DB RCT) 28% 0.72 [0.38-1.40] viral+ 12/60 16/58 RESERVOIR First Wa.. (DB RCT) 23% 0.77 [0.49-1.23] viral+ 20/60 25/58 RESERVOIR First Wa.. (DB RCT) 1% 0.99 [0.76-1.29] viral+ 39/60 38/58 RESERVOIR First Wa.. (DB RCT) -3% 1.03 [0.88-1.19] viral+ 52/60 49/58 Rank (DB RCT) 36% 0.64 [0.12-3.46] death 2/23 3/22 Rank (DB RCT) 70% 0.3 [0.00-9e+23] recov. time 23 (n) 23 (n) Rank (DB RCT) -6% 1.06 [0.46-2.47] recov. time 23 (n) 23 (n) Rank (DB RCT) 57% 0.4 [0.00-4e+20] no disch. 23 (n) 23 (n) Rank (DB RCT) 0% 1.00 [0.90-1.11] viral time 23 (n) 23 (n) PROTECT-V Humphrey (DB RCT) 0% 1.00 [0.14-7.07] death 2/826 2/825 PROTECT-V Humphrey (DB RCT) 80% 0.20 [0.01-4.16] ventilation 0/826 2/825 PROTECT-V Humphrey (DB RCT) 13% 0.87 [0.41-1.81] hosp. 13/826 15/825 PROTECT-V Humphrey (DB RCT) -2% 1.02 [0.79-1.32] symp. case 103/826 133/825 Niclosamide COVID-19 outcomes c19early.org February 2025 ​1​ CT: study uses combined treatment Favors niclosamide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0